Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Question for Whalewatcher

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Dec 29, 2021 6:36pm

68 Views

Post# 34269276

RE:RE:RE:RE:RE:RE:RE:RE:RE:Question for Whalewatcher

What I think is Whalewatcher1 is an ALL OUT CLOWN. Neither XORTX or Diamedica Therapeutics have any drugs in their pipeline that matches up with Algernon Pharmaceuticals. Try at least matching apples to apples - DMT - Chronic Cough - Small Cell Lung Cancer. Those are the diseases currently on the plate for debate. As to whatever Moreau may or may not have said about either of those companies, we know Moreau is a moron. Now go back to your coloring board and come up with some new BS to waste folks time on. Carry on...

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 13, 2024